NCT05263986 - The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions

Advanced or Metastatic Solid Tumor

Interventions

DRUG

MRTX849

"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."

Trial Locations (8)

Unknown

Beijing Cancer Hospital, Beijing

Chongqing University Cancer Hospital, Chongqing

Henan Cancer Hospital, Zhengzhou

Union hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan Cancer Hospital, Changsha

The first Hospital of Jilin University, Changchun

Lin Yi Cancer Hospital, Linyi

Shanghai Chest Hospital, Shanghai